Qiagen and Centogene announce genetic disease collaboration

Qiagen has announced a new collaboration and co-marketing agreement with Centogene in the field of rare genetic diseases.

The companies are looking to provide customers with more complete sample-to-insight research and clinical testing solutions, including the integration of the Centogene CentoMD rare disease variant database into Qiagen's bioinformatics offering to enhance test interpretation.

This database includes more than 4.5 million clinically annotated variants from 135,000 cases from over 115 countries of origin, with Qiagen to serve as the exclusive global commercial distribution partner of CentoMD going forward.

Additionally, Centogene will license Qiagen's bioinformatics solutions to support its rare disease diagnostic testing services, building on the existing data-sharing partnership they have been operating through the Allele Frequency Community.

Finally, the firms will work together to develop advanced machine-learning methods to improve clinical prediction of these diseases.

Dr Laura Furmanski, senior vice-president and head of Qiagen's bioinformatics business, said: "We are pleased to collaborate to make a difference for these patients and to broaden the rare and genetic disease solutions available for both companies' customers worldwide."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.